There exists a controversy in the causality of depression and diabetes. Depression is known to cause physical illness like diabetes and vice versa. This controversy has also been extended to the therapeutic scope of metformin in improving depressive symptoms among diabetic patients. The reported claim on the potential antidepressant activity of metformin is yet to be validated. The aim of the study was to investigate the antidepressant activity of metformin in acute models of depression. The antidepressant activity of metformin (100, 200 and 400 mg/kg) was investigated using the tail suspension test (TST) and the forced swim test (FST) in mice. The effect of metformin on exploratory behaviour was assessed using open field test (OFT). Metformin did not significantly alter the immobility time of mice in both TST and FST. Sertraline significantly (p ≤ 0.05 and p ≤ 0.01) decreased IMT in both TST and FST respectively. Metformin non-significantly alter number of line cross (NLC) significantly (p ≤ 0.01) decreased number of rearing (NR) only at 100 mg/kg. Diazepam significantly (p ≤ 0.01) increased NLC and significantly (p ≤ 0.05) decreased NR in OFT. Metformin does not possess antidepressant-like activity.